T he risk of development of chronic kidney disease (CKD) is 3-to 5-fold higher in the African American population. This increased risk has been partly attributed to 2 African ancestral genetic variants (termed G1 and G2) in the C-terminal domain of the APOL1 gene on chromosome 22. 1 G0 is the reference allele, not associated with kidney disease. G1 (rs73885319 and rs60910145) encodes 2 highly correlated nonsynonymous amino acid changes, whereas G2 (rs71785313) encodes a 2-amino acid deletion in the C-terminal region of APOL1. It is estimated that 20% of African Americans carry at least one APOL1 G1 or G2 risk allele, translating into close to 7.6 million people in the United States and more than a hundred million people worldwide. On the contrary, G1 and G2 alleles are absent in people of European ancestry because it developed after modern Europeans left Africa (≈4000 years ago). 2 People carrying 2 risk alleles have 7-to 30-fold increased risk of developing CKD. 3 The CKD development, on the other hand, shows high variability and, therefore, likely depends on environmental, or possibly additional genetic, factors. 4 For example, HIV infection in a person with 2 risk alleles leads to close to 100% penetrance of HIV-associated nephropathy. An unusual positive selection pressure might explain such high incidence of a disease-associated allele. 5 People with G1 or G2 APOL1 variant appear to be protected from Trypanosoma Brucei infection, which causes African Sleeping Sickness. 5
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The incidence of cardiovascular disease (CVD) is also higher in people of African descent. In the current issue of Arteriosclerosis, Thrombosis, and Vascular Biology, Mukamal et al 6 examined the association between APOL1 variants and CVD in the Cardiovascular Health Study (CHS). 7 They found that African Americans carrying 2 APOL1 risk alleles had increased risk of myocardial infarction (odds ratio of 1.8) and mortality. There was a similar association between carrying 2 APOL1 risk alleles and peripheral vascular disease (determined noninvasively by ankle-brachial index), but not with carotid intima media thickness. The reported differences in cardiovascular risk were likely not a consequence of CKD because there was no difference in glomerular filtration rate between the APOL1 high-risk versus low-risk genotype groups. Other atherosclerosis risk factors, including hypertension and lipid levels, were similar when low-and high-risk genotype groups were compared. There was a small but statistically significant difference in albuminuria levels between the 2 groups. CHS African Americans with 2 APOL1 risk alleles had 27.9 mg/g of urinary albumin levels, whereas the low-risk genotype subjects had only 14.6 mg/g.
The manuscript adds to the recent debate on whether APOL1 risk variant is associated with increased cardiovascular risk and whether the increased cardiovascular risk observed in people with APOL1 variants is simply the consequence of the renal functional abnormalities. In the Jackson Heart Study (JHS), Ito et al reported a statistically significant association between APOL1 risk variants and incident CVD. 8 The Seidman group also replicated these findings in the Women's Health Initiative. 8 Interestingly, there was no association of the APOL1 risk genotype with intermediate phenotypes, such as changes in left ventricular geometry, and paradoxically, coronary artery calcification scores were lower in the 2 risk allele group. Similar to Mukamal et al, the association with CVD events reported by Ito et al were independent of CKD or traditional CVD risk factors. 6 On the other hand, Langefeld et al examined this association in the Systolic Blood Pressure Intervention (SPRINT) Trial. 9 Although the group was able to confirm the association between APOL1 high-risk genotype and CKD development, including albuminuria and glomerular filtration rate, they were unable to identify an association between APOL1 risk allele and CVD.
At face value, it is hard to reconcile such different results among studies examining essentially the same hypothesis: the association between APOL1 risk alleles and CVD. The study design and outcome ascertainment differences might actually explain such differences. The study of Langefeld et al used a cross-sectional approach with the outcome defined as prevalent CVD by self-reported history of myocardial infarction, coronary or carotid artery revascularization. By contrast, JHS/ Women's Health Initiative and CHS used a prospective study design (time-to-event) in which CVD outcomes were adjudicated by physician chart review. Prospective studies of adjudicated incident CVD events can avoid baseline differences that might be attributed to selection bias. Future larger studies might help to reconcile these differences.
An important limitation of the APOL1-CVD studies reported to date is that they are relatively small, with <100 CVD events per study. Although CVD genomics consortia,
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February 2016 such as CARDIoGRAM, include tens of thousands of cases and have identified genetic risk factors for coronary heart disease in populations of European ancestry, 10 similar well-organized, large-scale coronary heart disease efforts are lacking in under-represented minority populations, such as African Americans. Furthermore, albuminuria (even low grade) is known to have a strong association with CVD development. 11 In the current article, Mukamal et al argues that the almost 2-fold increase in cardiovascular risk cannot be explained by the small change in albuminuria; in the future, more direct studies will be needed to determine whether the increased CVD is mediated by albuminuria. Another point of controversy has been whether the APOL1 risk genotype predisposes to kidney or CVD development in patients with diabetes mellitus. 11 Studies from the Chronic Renal Insufficiency Cohort (CRIC) detected a significant (2-fold) risk of kidney function decline in diabetic subjects. 4 Other studies have observed no association between APOL1 and CKD in diabetics, and Freedman et al even reported a protective effect for subjects with diabetes mellitus. 12 Therefore, the proportion of patients with diabetes mellitus included in studies examining CVD outcomes can also potentially influence the outcome of these results.
What is the mechanism of the purported association between APOL1 and CVD risk? APOL1 is expressed in vascular tissue, suggesting a pathogenic link with atherosclerosis. Innate immunity pathways involving toll-like receptors and interferon have recently been invoked in the pathogenesis of APOL1-associated CKD. 13 In addition to its trypanolytic function, circulating APOL1 binds to high-density lipoprotein (HDL)-3 particles that also contain apolipoprotein A1 and the hemoglobin-binding, haptoglobin-related protein. 1 Recent data suggest an association between the number of APOL1 risk alleles and the distribution of HDL particle sizes or subclass concentration in African Americans. 14 Further study of the role of innate immune mechanisms and altered HDL metabolism into the mechanisms of CKD and CVD susceptibility should be evaluated.
As we enter the era of Precision Medicine, the evaluation of APOL1 susceptibility alleles in individuals of African ancestry may ultimately provide important information to improve clinical care with respect to CKD, and possibly CVD, and reduce the high burden of these chronic diseases in the African American population. 15 Larger African American studies that include a much larger number of CVD events, combined with additional exposure and genetic data, are likely required to clarify the role of APOL1 as a CVD risk factor among the African American population and any differential effect by diabetes status or other common genetic or environmental risk factors. An improved understanding of APOL1 in vascular biology and inflammation may help delineate the mechanisms that underlie its association with both CVD and CKD disease and identify new therapeutic options for slowing disease progression.
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